Hydronephrosis Market Report 2026

The hydronephrosis market size has grown rapidly in recent years. It will grow from $3.38 billion in 2025 to $3.74 billion in 2026 at a compound annual growth rate (CAGR) of 10.4%. The growth in the historic period can be attributed to improvements in diagnostic imaging technologies, rising incidence of kidney stones, increased awareness of renal disorders, expansion of hospital infrastructure, availability of surgical intervention options.

The hydronephrosis market size is expected to see rapid growth in the next few years. It will grow to $5.48 billion in 2030 at a compound annual growth rate (CAGR) of 10.1%. The growth in the forecast period can be attributed to increasing aging population, rising prevalence of chronic kidney diseases, growing adoption of precision medicine approaches, expansion of advanced urology treatment centers, increased focus on early-stage diagnosis. Major trends in the forecast period include increasing use of advanced imaging diagnostics, rising adoption of minimally invasive treatment techniques, growing focus on early disease detection, expansion of integrated diagnostic and treatment pathways, enhanced monitoring of renal function.

The increasing prevalence of kidney diseases is expected to drive the growth of the hydronephrosis market in the coming years. Kidney disease, also referred to as renal disease or nephropathy, encompasses a range of conditions that cause damage to the kidneys and impair their ability to effectively filter blood. The rise in kidney disease cases is attributed to multiple factors, including the growing incidence of diabetes and hypertension, increasing obesity rates, an aging population, and genetic and ethnic influences. Hydronephrosis is managed by treating the underlying cause of urinary obstruction, which may involve medications, surgical procedures, or other therapeutic interventions to restore normal urine flow. For example, in June 2023, according to a report published by Kidney Research UK, a UK-based non-profit organization, approximately 7.2 million people in the UK are currently living with chronic kidney disease, accounting for more than 10% of the population. Among them, 3.25 million individuals are in advanced stages of the condition, while an additional 3.9 million are in the early stages. By 2033, the number of people affected by chronic kidney disease is projected to reach 7.61 million. Consequently, the rising burden of kidney diseases is supporting the expansion of the hydronephrosis market.

Leading companies operating in the hydronephrosis market are focusing on the development of innovative products, such as drainage catheters, to improve patient care by offering efficient and minimally invasive solutions for urine drainage from the kidneys. Drainage catheters are medical devices used to remove fluids, including urine or blood, from the body to relieve pressure or prevent fluid buildup. For instance, in October 2024, Argon Medical Devices Inc., a US-based manufacturer of specialty medical products, introduced the SKATER mini-loop drainage catheter. This device is designed for the minimally invasive drainage of unwanted fluid collections and is inserted through the skin under imaging guidance. It features a loop that is 40% smaller, allowing secure placement and effective drainage from smaller cavities. Recognized for its durability, resistance to kinking, and compatibility with alcohol, the catheter improves usability in interventional procedures. By expanding Argon’s drainage product portfolio, the SKATER Mini-Loop is intended to enhance patient outcomes and streamline drainage procedures for healthcare professionals.

In October 2023, Laborie Medical Technologies Corp., a US-based diagnostic company, acquired Urotronic Inc. for an undisclosed amount. This acquisition strengthens Laborie’s urology portfolio by adding established and innovative solutions for physicians and patients globally. It also supports Laborie’s efforts to advance next-generation technologies that address unmet medical needs and deliver solutions aimed at preserving and restoring human dignity. Urotronic Inc. is a US-based medical device company specializing in the development of innovative treatments for urological disorders.

Major companies operating in the hydronephrosis market are Boston Scientific Corporation, Medtronic PLC, Cook Medical, Coloplast A/S, B. Braun Group, KARL STORZ SE & Co. KG, Olympus Corporation, Richard Wolf GmbH, Teleflex Incorporated, BD, Terumo Corporation, UroGen Pharma Ltd., Urologix Inc., C. R. Bard, ConvaTec Group PLC, AngioDynamics Inc., Merit Medical Systems Inc., NxStage Medical Inc., Fresenius Medical Care, Nipro Corporation.

North America was the largest region in the hydronephrosis market in 2025. The regions covered in the hydronephrosis market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the hydronephrosis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are influencing the hydronephrosis market by increasing costs of imported diagnostic imaging equipment, surgical instruments, catheters, and medical devices used in treatment and diagnosis. Hospitals and specialty clinics in North America and Europe are most affected due to reliance on imported medical technologies, while Asia-Pacific faces cost pressure on device manufacturing. These tariffs are increasing treatment costs and slowing equipment upgrades. However, they are also supporting domestic medical device production and regional supplier diversification.

The hydronephrosis market research report is one of a series of new reports that provides hydronephrosis market statistics, including hydronephrosis industry global market size, regional shares, competitors with a hydronephrosis market share, detailed hydronephrosis market segments, market trends and opportunities, and any further data you may need to thrive in the hydronephrosis industry. This hydronephrosis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Hydronephrosis is a medical condition marked by the dilation of one or both kidneys resulting from the accumulation of urine. This condition develops when normal urine flow is obstructed, leading to kidney enlargement. It may be caused by blockages such as kidney stones, tumors, or anatomical abnormalities, and can potentially result in kidney damage if not treated in a timely manner.

The primary types of hydronephrosis include unilateral hydronephrosis and bilateral hydronephrosis. Unilateral hydronephrosis occurs when a single kidney becomes enlarged due to urine buildup caused by an obstruction or other abnormalities in the urinary tract on one side. It is categorized based on its cause as either intrinsic or extrinsic. Diagnosis is mainly conducted through laboratory testing and imaging techniques. Available treatment approaches include shock wave lithotripsy, laparoscopy, bladder catheterization, steroid therapy, and other interventions.

The hydronephrosis market includes revenues earned by entities by providing services such as urine flow monitoring, follow-up care, and minimally invasive procedures. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.